aTyr Pharma (FRA:471A) Cyclically Adjusted FCF per Share: €-6.06 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:471A aTyr Pharma Inc FRA:471A
21 GF Score
Price €0.38
GF Value €0.35
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is aTyr Pharma Cyclically Adjusted FCF per Share?

aTyr Pharma FRA:471A +4.40% 21 Cyclically Adjusted FCF per Share is €-6.06 as of Jun. 2026. GuruFocus rates FRA:471A with a GF Score™ of 21/100 and a GF Value™ of €0.35 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

aTyr Pharma's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.083. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-6.06 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-15), aTyr Pharma's current stock price is €0.38. aTyr Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-6.06. aTyr Pharma's Cyclically Adjusted Price-to-FCF of today is .


aTyr Pharma  (FRA:471A) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


aTyr Pharma Cyclically Adjusted FCF per Share Related Terms


aTyr Pharma Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for aTyr Pharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

aTyr Pharma Cyclically Adjusted FCF per Share Chart

aTyr Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -16.25 -13.79 -8.40

aTyr Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.07 -11.59 -8.40 -7.01 -6.06

FRA:471A vs IBO, BYSI, MCRB: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, aTyr Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


aTyr Pharma Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, aTyr Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where aTyr Pharma's Cyclically Adjusted Price-to-FCF falls into.


FRA:471A
21GF Score
aTyr Pharma Inc FRA:471A
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

aTyr Pharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, aTyr Pharma's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.083/333.9520*333.9520
=-0.083

Current CPI (Jun. 2026) = 333.9520.

aTyr Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -7.763 241.428 -10.738
201612 -6.571 241.432 -9.089
201703 -7.801 243.801 -10.686
201706 -5.089 244.955 -6.938
201709 -4.247 246.819 -5.746
201712 -4.137 246.524 -5.604
201803 -4.221 249.554 -5.649
201806 -3.706 251.989 -4.911
201809 -2.607 252.439 -3.449
201812 -1.964 251.233 -2.611
201903 -2.207 254.202 -2.899
201906 -1.315 256.143 -1.714
201909 -1.011 256.759 -1.315
201912 -1.145 256.974 -1.488
202003 0.249 258.115 0.322
202006 -0.609 257.797 -0.789
202009 -0.490 260.280 -0.629
202012 -0.414 260.474 -0.531
202103 -0.348 264.877 -0.439
202106 -0.401 271.696 -0.493
202109 -0.540 274.310 -0.657
202112 -0.257 278.802 -0.308
202203 -0.332 287.504 -0.386
202206 -0.309 296.311 -0.348
202209 -0.448 296.808 -0.504
202212 -0.372 296.797 -0.419
202303 -0.041 301.836 -0.045
202306 -0.241 305.109 -0.264
202309 -0.164 307.789 -0.178
202312 -0.171 306.746 -0.186
202403 -0.312 312.332 -0.334
202406 -0.263 314.175 -0.280
202409 -0.157 315.301 -0.166
202412 -0.152 315.605 -0.161
202503 -0.165 319.799 -0.172
202506 -0.134 322.561 -0.139
202509 -0.180 324.800 -0.185
202512 -0.106 324.054 -0.109
202603 -0.112 330.213 -0.113
202606 -0.083 333.952 -0.083

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-6.06 mean?
aTyr Pharma (FRA:471A) has a Cyclically Adjusted FCF per Share of €-6.06 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on aTyr Pharma and its competitors.
Is aTyr Pharma's Cyclically Adjusted FCF per Share too high?
aTyr Pharma's current Cyclically Adjusted FCF per Share is €-6.06. Overall, aTyr Pharma has a GF Score™ of 21/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's Cyclically Adjusted FCF per Share compare to IBO and BYSI?
aTyr Pharma's Cyclically Adjusted FCF per Share of €-6.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on aTyr Pharma and its competitors. aTyr Pharma's current Cyclically Adjusted FCF per Share is €-6.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (FRA:471A) is currently considered Fairly Valued. The stock's GF Value™ is €0.35, compared to a current price of €0.38 — trading 8.6% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-6.06. aTyr Pharma's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For aTyr Pharma (FRA:471A), the current Cyclically Adjusted FCF per Share is €-6.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is aTyr Pharma (FRA:471A) Overvalued in 2026?

Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued. The current stock price of €0.38 is trading 8.6% above its estimated GF Value™ of €0.35. GuruFocus considers aTyr Pharma to be Fairly Valued.

Key valuation signals for FRA:471A:

  • Cyclically Adjusted FCF per Share: €-6.06
  • GF Value™: €0.35 vs. price of €0.38 (8.6% above fair value)
  • GF Score™: 21/100 with 3 warning signs

No single metric tells the full story. See the FRA:471A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


aTyr Pharma Business Description

Other Exchanges ATYR:USA471A:Germany
Address 10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
21GF Score

Get the complete analysis for FRA:471A

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.38
Price
€0.35
GF Value